The UK and US have signed a major commercial pact that will maintain no duties on UK drug products being sold in the American market.
The Terms of the Accord
As part of the deal, the UK has agreed to increase spending on medicines through the public health system. This pledge guarantees that duties on these vital exports will stay at zero for a duration of the next three years.
This deal is in response to previous statements to significantly raise duties on branded drug products, with figures discussed as high as 100%.
"This arrangement with the UK reinforces the global environment for cutting-edge drugs and brings much-needed equity to transatlantic pharmaceutical trade," a statement noted.
Trade Impact
Medicines represent one of the Britain's most significant goods shipped to the America, which is easily the biggest destination for leading British pharmaceutical firms.
Export figures show that in the year prior to the third quarter, the UK exported drugs valued at over eleven billion pounds to the US. This figure made up 17.4% of British export trade in that span.
"This agreement safeguards work, increases capital expenditure and facilitates the UK to emerge as a international leader for biotech and pharma," a minister remarked.
Key British Pledges
The pact entails several key commitments from the United Kingdom:
- Price Threshold Increase: The UK will increase the affordability limit at which it considers new treatments to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a aim to raise total public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years.
- Rebate Cap: The percentage pharmaceutical firms must pay back to the NHS to prevent overspending will be restricted at fifteen percent. Last year, refunds exceeded 20%.
Recent Tensions
This agreement follows a protracted tension between the drug companies and the British authorities over medicine costs and approval rates.
This friction were heightened by arguments that American patients were charged several times more for the equivalent treatments than patients in the Britain and the EU.
Recently, several large drug company projects in the UK have been paused or scrapped, while substantial funding commitments have been pledged toward American operations.
A senior figure acknowledged that the NHS needed to increase expenditure on treatments, noting that its spending on drugs had declined as a proportion of its resources over the previous ten-year period.
